These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 10362090)

  • 21. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
    Dranoff G; Jaffee E; Lazenby A; Golumbek P; Levitsky H; Brose K; Jackson V; Hamada H; Pardoll D; Mulligan RC
    Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3539-43. PubMed ID: 8097319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines.
    Klein C; Bueler H; Mulligan RC
    J Exp Med; 2000 May; 191(10):1699-708. PubMed ID: 10811863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of antigen-specific tumor immunity by genetic and cellular vaccines against MAGE: enhanced tumor protection by coexpression of granulocyte-macrophage colony-stimulating factor and B7-1.
    Büeler H; Mulligan RC
    Mol Med; 1996 Sep; 2(5):545-55. PubMed ID: 8898371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma.
    Sandler AD; Chihara H; Kobayashi G; Zhu X; Miller MA; Scott DL; Krieg AM
    Cancer Res; 2003 Jan; 63(2):394-9. PubMed ID: 12543793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccination for experimental gliomas using GM-CSF-transduced glioma cells.
    Herrlinger U; Kramm CM; Johnston KM; Louis DN; Finkelstein D; Reznikoff G; Dranoff G; Breakefield XO; Yu JS
    Cancer Gene Ther; 1997; 4(6):345-52. PubMed ID: 9408604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
    Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
    Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
    Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Lim M; Weber CE; Baccala AA; Goemann MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF; Nelson WG
    Cancer Res; 1999 Oct; 59(20):5160-8. PubMed ID: 10537292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunization with a syngeneic tumor infected with recombinant vaccinia virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) induces tumor regression and long-lasting systemic immunity.
    McLaughlin JP; Abrams S; Kantor J; Dobrzanski MJ; Greenbaum J; Schlom J; Greiner JW
    J Immunother; 1997 Nov; 20(6):449-59. PubMed ID: 9409450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Ishida K; Primus FJ; Yamaue H
    Int J Cancer; 2007 Feb; 120(3):585-93. PubMed ID: 17096339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor.
    Chang AE; Li Q; Bishop DK; Normolle DP; Redman BD; Nickoloff BJ
    Hum Gene Ther; 2000 Apr; 11(6):839-50. PubMed ID: 10779161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T cell antitumor response.
    Gri G; Gallo E; Di Carlo E; Musiani P; Colombo MP
    J Immunol; 2003 Jan; 170(1):99-106. PubMed ID: 12496388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [GM-CSF gene-modified dendritic cell vaccine enhances antitumor immunity in vitro].
    He SB; Sun K; Wang L; Li DC; Zhang YY
    Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):410-4. PubMed ID: 20819479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of Fasl and GM-CSF confers synergistic antitumor immunity in an in vivo model of the murine Lewis lung carcinoma.
    Ho MY; Sun GH; Leu SJ; Ka SM; Tang SJ; Sun KH
    Int J Cancer; 2008 Jul; 123(1):123-33. PubMed ID: 18386791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Flt3 ligand antitumor activity in a murine breast cancer model: a comparison with granulocyte-macrophage colony-stimulating factor and a potential mechanism of action.
    Braun SE; Chen K; Blazar BR; Orchard PJ; Sledge G; Robertson MJ; Broxmeyer HE; Cornetta K
    Hum Gene Ther; 1999 Sep; 10(13):2141-51. PubMed ID: 10498246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human autologous in vitro models of glioma immunogene therapy using B7-2, GM-CSF, and IL12.
    Parney IF; Farr-Jones MA; Kane K; Chang LJ; Petruk KC
    Can J Neurol Sci; 2002 Aug; 29(3):267-75. PubMed ID: 12195617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells.
    Qin Z; Noffz G; Mohaupt M; Blankenstein T
    J Immunol; 1997 Jul; 159(2):770-6. PubMed ID: 9218594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of T-cell apoptosis in rats by genetically engineered glioma cells expressing granulocyte-macrophage colony-stimulating factor and B7.1.
    Tseng SH; Chen Y; Chang CJ; Tai KF; Lin SM; Hwang LH
    Clin Cancer Res; 2005 Feb; 11(4):1639-49. PubMed ID: 15746069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma.
    Driessens G; Hoffmann P; Pouwels M; Zlotta A; Schulman C; Velu T; Bruyns CA
    J Immunother; 2009; 32(2):140-4. PubMed ID: 19238012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.